Literature DB >> 10080412

Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris.

R van der Does1, U Hauf-Zachariou, E Pfarr, W Holtbrügge, S König, M Griffiths, A Lahiri.   

Abstract

In a double-blind, randomized, 3-month multicenter study, the safety and tolerability and the antianginal and anti-ischemic efficacy of carvedilol 25 to 50 mg twice daily were assessed in comparison with metoprolol 50 to 100 mg twice daily in younger and elderly patients with stable angina. After a 7-day placebo run-in at the end of which a symptom-limited bicycle ergometric exercise was performed, 368 patients were randomly allocated to the parallel treatment groups. After 4 weeks of therapy with a low dose, a further exercise test was performed and patients were titrated in single-blind fashion to the higher dose if the increase in total exercise time was < 1 minute, and there was no safety concern. After a further 8 weeks of treatment a third exercise test was performed. Carvedilol low dose/high dose was shown to be at least as safe and well tolerated as metoprolol low dose/high dose both in younger and elderly patients. There were no hitherto unknown adverse events and no marked change in the types of events after increase of the doses. Early adverse events after treatment initiation or uptitration were equal with both medications, indicating no particular risk associated with carvedilol's vasodilatory action. No rebound phenomena were observed. Both drugs showed good antianginal and anti-ischemic efficacy, with marked increases on uptitration including patients > or = 65 years of age. However, in the doses selected, which appeared equipotent with respect to beta blockade, carvedilol's improvement of time to 1-mm ST-segment depression was statistically significantly greater than that of metoprolol. This could be due to its additional vasodilatory or antioxidative actions. Based on the safety and efficacy data of the present study, use of the higher of the 2 recommended doses of carvedilol and metoprolol appears justified in younger and elderly patients without adequate therapeutic control at lower doses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080412     DOI: 10.1016/s0002-9149(98)00960-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

Review 2.  Novel treatment approaches in hypertensive type 2 diabetic patients.

Authors:  Yaniel Castro Torres; Richard E Katholi
Journal:  World J Diabetes       Date:  2014-08-15

Review 3.  Stable angina pectoris: antianginal therapies and future directions.

Authors:  Bernard R Chaitman; Abhay A Laddu
Journal:  Nat Rev Cardiol       Date:  2011-08-30       Impact factor: 32.419

Review 4.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889

5.  Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting.

Authors:  Jennifer J Schimmer; Sarah J Billups; Thomas Delate
Journal:  Pharm Pract (Granada)       Date:  2009-03-15

6.  Long-term efficacy of vasodilating β-blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry.

Authors:  Jaehoon Chung; Jung-Kyu Han; Han-Mo Yang; Kyung-Woo Park; Hyun-Jae Kang; Bon-Kwon Koo; Myung Ho Jeong; Hyo-Soo Kim
Journal:  Korean J Intern Med       Date:  2020-07-03       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.